Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to fight teen pain: a new hope?

NCT ID NCT07785362

Symptom relief Sponsor: Istituto Giannina Gaslini Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests whether transcranial electrical stimulation (tES) — a safe, non-invasive technique that sends a mild electrical current through the scalp — can reduce pain and improve quality of life in children and adolescents aged 10 to 21 with juvenile fibromyalgia or other non-inflammatory musculoskeletal pain syndromes. Participants are randomly assigned to receive either active tES or a sham (placebo) stimulation for 20 minutes a day over two weeks. The study measures changes in pain, quality of life, and brain activity to see if this approach could be a helpful addition to chronic pain management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial electrical stimulation (tES), a non-invasive brain stimulation technique
What this could lead to
If effective, tES could offer a drug-free, non-invasive option to help young people with chronic musculoskeletal pain feel better and improve their daily lives.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not apply broadly. The treatment may not outperform a placebo, and its long-term safety and effectiveness are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects aged between 10 and 21 years.Patients with fibromyalgia according to the 1990 criteria of the American College of Rheumatology or Patients with other types of non-inflammatory musculoskeletal pain syndromes.Patients who reported a mean pain score \> 4 on a 10-point visual analog scale (VAS) during the two weeks preceding the clinical trial.Disease duration for more than 6 months, no change in drug treatments during the last month, and lack of response to conventional treatments. Exclusion Criteria: iagnosis of epilepsy or at risk of seizuresPresence of a cardiac pacemakerPresence of an implanted infusion pump, metal plates in the skull, or metal objects in the eye and skull (e.g., after neurosurgical interventions)Past or present history of substance abusePast or present history of neuropsychiatric disorders (major depression and schizophrenia)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRPS (complex regional pain syndromes) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complex regional pain syndrome fibromyalgia Sedentary Behavior somatoform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRPS (complex regional pain syndromes) Fibromyalgia Juvenile Neuromodulation Pain syndrome Physical disability Physical inactivity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ronchetti Anna Bruna

    Genova, GE, 16147, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.